169 related articles for article (PubMed ID: 29914436)
1. Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems.
Greasley RU; Turner R; Collins K; Brown J; Bourke L; Rosario DJ
BMC Cancer; 2018 Jun; 18(1):667. PubMed ID: 29914436
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer.
Davda R; Hughes S; Jones R; Crabb SJ; Troup J; Payne H
Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):376-85. PubMed ID: 26874654
[TBL] [Abstract][Full Text] [Related]
3. A multi-centre investigation of delivering national guidelines on exercise training for men with advanced prostate cancer undergoing androgen deprivation therapy in the UK NHS.
Bourke L; Turner R; Greasley R; Sutton E; Steed L; Smith D; Brown J; Kelly B; Hulme C; Greenfield D; Persad R; Farrin A; Hewison J; Rosario DJ;
PLoS One; 2018; 13(7):e0197606. PubMed ID: 29975707
[TBL] [Abstract][Full Text] [Related]
4. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
5. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
Shore ND; Drake CG; Lin DW; Ryan CJ; Stratton KL; Dunshee C; Karsh LI; Kaul S; Kernen K; Pieczonka C; Sieber P; Stewart C; Williams M; Concepcion RS
Prostate; 2020 Oct; 80(14):1159-1176. PubMed ID: 32779781
[TBL] [Abstract][Full Text] [Related]
7. The development of a theory and evidence-based intervention to aid implementation of exercise into the prostate cancer care pathway with a focus on healthcare professional behaviour, the STAMINA trial.
Turner RR; Arden MA; Reale S; Sutton E; Taylor SJC; Bourke L; Greenfield DM; Morrissey D; Brown J; Doherty P; Rosario DJ; Steed L
BMC Health Serv Res; 2021 Mar; 21(1):273. PubMed ID: 33766001
[TBL] [Abstract][Full Text] [Related]
8. Management of patients with castration-resistant prostate cancer (CRPC): results of an Italian survey using the delphi method.
Terrone C; Berruti A; Papotti M; Vavassori V; Sciarra A
Tumori; 2016 Oct; 102(5):514-520. PubMed ID: 26166221
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial.
Owen PJ; Daly RM; Livingston PM; Mundell NL; Dalla Via J; Millar JL; Fraser SF
Trials; 2017 Oct; 18(1):451. PubMed ID: 28974267
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta.
García de Paredes Esteban JC; Alegre Del Rey EJ; Asensi Díez R
Farm Hosp; 2017 Jul; 41(4):550-558. PubMed ID: 28683707
[TBL] [Abstract][Full Text] [Related]
11. [Options of Chemotherapy in the Treatment of Prostate Cancer].
Richter I; Dvořák J; Bartoš J
Klin Onkol; 2017; 30(1):28-33. PubMed ID: 28185462
[TBL] [Abstract][Full Text] [Related]
12. "Kicked out into the real world": prostate cancer patients' experiences with transitioning from hospital-based supervised exercise to unsupervised exercise in the community.
Schmidt MLK; Østergren P; Cormie P; Ragle AM; Sønksen J; Midtgaard J
Support Care Cancer; 2019 Jan; 27(1):199-208. PubMed ID: 29931489
[TBL] [Abstract][Full Text] [Related]
13. Emerging therapies in castration resistant prostate cancer.
Thoreson GR; Gayed BA; Chung PH; Raj GV
Can J Urol; 2014 Apr; 21(2 Supp 1):98-105. PubMed ID: 24775731
[TBL] [Abstract][Full Text] [Related]
14. Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials.
van Soest RJ; de Wit R
BMC Med; 2015 Dec; 13():304. PubMed ID: 26695172
[TBL] [Abstract][Full Text] [Related]
15. Patients' and partners' views of care and treatment provided for metastatic castrate-resistant prostate cancer in the UK.
Catt S; Matthews L; May S; Payne H; Mason M; Jenkins V
Eur J Cancer Care (Engl); 2019 Nov; 28(6):e13140. PubMed ID: 31475410
[TBL] [Abstract][Full Text] [Related]
16. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
Anantharaman A; Small EJ
Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
[TBL] [Abstract][Full Text] [Related]
17. Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer.
Peppercorn J; Armstrong A; Zaas DW; George D
Urol Oncol; 2013 Oct; 31(7):1079-84. PubMed ID: 22305627
[TBL] [Abstract][Full Text] [Related]
18. The provision of dietary and physical activity advice for men diagnosed with prostate cancer: a qualitative study of the experiences and views of health care professionals, patients and partners.
Sutton E; Hackshaw-McGeagh LE; Aning J; Bahl A; Koupparis A; Persad R; Martin RM; Lane JA
Cancer Causes Control; 2017 Apr; 28(4):319-329. PubMed ID: 28220328
[TBL] [Abstract][Full Text] [Related]
19. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
